What To Expect From Cleveland-Cliffs Stock's Q1?
KYIV, UKRAINE - 2024/01/24: In this photo illustration, the Cleveland-Cliffs Inc. (CCI) logo is seen ... More on a smartphone and a PC screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)
Cleveland-Cliffs (NYSE:CLF) plans to release its earnings on May 7, 2025. According to our estimates, revenues are expected to reach $5.2 billion, while the consensus estimates for earnings forecast a loss of $0.83 per share. This anticipated loss is mainly due to declining steel prices and weaker demand in essential sectors such as automotive and construction. The company is facing challenges from falling U.S. hot-rolled coil (HRC) prices, which have decreased to approximately $665 per ton. This drop, alongside rising inventory levels and shorter lead times, indicates a weakening market environment that could affect Cleveland-Cliffs' revenue and profitability.
The company currently has a market capitalization of $4.0 billion. Over the past twelve months, it recorded $19 billion in revenue, but was operationally loss-making with operating losses of $504 million and a net income of $754 million in losses. However, if you are looking for upside potential with lower volatility compared to individual stocks, the Trefis High Quality portfolio offers an alternative – having outperformed the S&P 500 and generating returns exceeding 91% since its inception.
View earnings reaction history of all stocks
Here are some insights on one-day (1D) post-earnings returns:
Additional insights into the 5-Day (5D) and 21-Day (21D) returns following earnings are consolidated along with the statistics in the table below.
CLF 1D, 5D, and 21D Post Earnings Return
A comparatively less risky approach (albeit less useful if the correlation is weak) is to examine the correlation between short-term and medium-term returns post-earnings, identify a combination with the highest correlation, and execute the corresponding trade. For instance, if 1D and 5D exhibit the highest correlation, a trader might choose to take a "long" position for the subsequent 5 days if the 1D post-earnings return is positive. Here is some correlation data derived from 5-year and 3-year (more recent) history. Note that the correlation notation 1D_5D refers to the correlation between 1D post-earnings returns and subsequent 5D returns.
CLF Correlation Between 1D, 5D, and 21D Historical Returns
At times, the performance of peers can affect the post-earnings stock response. In fact, the pricing impact might begin prior to the earnings announcements. Below is some historical data comparing the post-earnings performance of Cleveland-Cliffs stock against the stock performance of peers that reported earnings just before Cleveland-Cliffs. For a fair comparison, peer stock returns also represent post-earnings one-day (1D) returns.
CLF Correlation With Peer Earnings
Discover more about Trefis RV strategy that has outperformed its all-cap stocks benchmark (a mix of all three, the S&P 500, S&P mid-cap, and Russell 2000), yielding strong returns for investors. Additionally, if you desire upside with a more stable ride than an individual stock like Cleveland-Cliffs, consider the High Quality portfolio, which has surpassed the S&P and achieved over 91% returns since its inception.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
IQVIA Holdings (NYSE:IQV) Sees 11% Share Price Rise Over Last Week
IQVIA Holdings experienced a 10% rise in share price over the last week, correlating with its recent developments, notably the dosing of the first patient in the RENEW Phase 2 trial and its strategic alliance with Sarah Cannon Research Institute to optimize oncology trials. These initiatives likely provided a positive sentiment boost, aligning well with the broader market momentum, as indices such as the S&P 500 also reached new highs. The market's anticipation over US-China trade talks and overall strong corporate earnings have supported the upward trend, further enhancing IQV's market performance. We've identified 1 warning sign for IQVIA Holdings that you should be aware of. Uncover 18 companies that survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. The recent 10% rise in IQVIA Holdings' share price has been influenced by important developments like the dosing in the RENEW Phase 2 trial and a key alliance with Sarah Cannon Research Institute. These initiatives are expected to potentially drive revenue growth, particularly as the strategic alliance optimizes oncology trials. The company's past performance, with total returns of 10.45% over five years, suggests modest growth in investor value. However, compared to the US Life Sciences industry's one-year return of 27% decline, IQVIA's recent rise highlights positive market sentiment. These initiatives, combined with FDA reforms and NVIDIA collaboration, may lower operational costs and have a favorable impact on earnings forecasts. Analysts predict revenue to grow by 5.2% annually over the next three years, which is somewhat cautious compared to the general expectations for the life sciences sector. The recent share price movement to US$146.2 remains below the consensus price target of US$216.31, indicating potential for future appreciation if the projected growth in revenue and earnings materializes. Click here to discover the nuances of IQVIA Holdings with our detailed analytical financial health report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:IQV. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25 minutes ago
- Yahoo
'So bad, it's good': History shows the market's smallest stocks may be poised for a rebound after record underperformance
Small-cap stocks look poised for a rebound this month after tariff-related losses. Historically, June sees strong small-cap performance due to FTSE Russell index rebalancing. Cheap valuations, potential rate cuts, and AI adoption could drive a small-cap resurgence. Small-cap stocks were hammered in the aftermath of President Donald Trump's tariffs, but the stage looks set for a rebound this June. The small-cap track record has been grim recently: the Russell 2000 has seen its worst streak of underperformance relative to the S&P 500 since the dot-com era, and this past May marked the sixth-worst year-to-date performance since 1990. Small caps, initially perceived as a clear winner of the Trump trade following the election, have emerged as the biggest losers of the trade war. With tariff concerns top-of-mind, investors are viewing small caps as "price takers, not price makers," extra vulnerable to inflation and supply chain disruptions, a note by Evercore ISI senior managing direction, Julian Emanuel, said. But for the optimists, once you hit rock bottom, the only direction to go is up. In the eyes of Evercore, small caps have become "so bad, they're good." June has historically been a strong month for small caps, as the FTSE Russell rebalances its indexes and adds or removes stocks based on market cap criteria. This leads to a surge of trading activity that can boost stock prices. This effect is particularly prominent in the wake of outsized underperformance. In the five other instances of disappointing January to May performance, small caps exhibited strong seasonal reversion during the month of June, outperforming large caps by an average of 4.1%, Evercore said. The firm believes the market has moved past the point of peak tariff uncertainty, which could further boost the sector's performance in June. There are other catalysts for a small-cap resurgence as well. Amy Zhang, a portfolio manager at investment management firm Alger, pointed to cheap valuations and the potential for rate cuts. Small caps have historically traded at a 27% premium relative to large caps due to their higher growth expectations, but on a forward-looking basis, the Russell 2000 is currently only trading at a 11% premium to the S&P 500. This allows investors to get exposure to small caps at a steep discount relative to history, especially as fundamentals and the overall economic environment improve. Cheap valuations make small caps appealing takeover targets, and a pickup in M&A activity could help lift the group, Zhang told Business Insider. As large companies look to boost growth through acquisitions, smaller firms become prime candidates. The healthcare sector, the largest component of the Russell 2000, tends to benefit the most from increased dealmaking, according to Bank of America. Both Emanuel and Zhang believe lower rates, which help smaller companies with higher levels of debt on their balance sheets, could be coming later this year. "Because it's data dependent, they run the risk of being too late again," Zhang said of the Fed cutting rates. "I think it could be the case, like last year Q4, where the Fed may be in a position again to pivot to 50 basis points of cuts." Additionally, Zhang sees AI as a long-term tailwind for small caps. "AI is very deflationary, especially for labor costs," Zhang said. That means companies that adopt AI effectively can expand margins and boost productivity — advantages that could be especially powerful for smaller firms with with smaller budgets. Read the original article on Business Insider
Yahoo
25 minutes ago
- Yahoo
Applied Medical Technology, Inc. Unveils Redesigned Mobile App Aligned with Recent Website Refresh
BRECKSVILLE, Ohio., June 10, 2025 /PRNewswire/ -- Applied Medical Technology, Inc. (AMT), a leader in innovative medical devices, is proud to announce the launch of its redesigned mobile application, AMT ONE Source®. This strategic update follows a successful website redesign completed late 2024, ensuring that both platforms now offer a cohesive, user-friendly digital experience. Enhancing User Experience Across PlatformsThe redesigned mobile app mirrors the modern, intuitive design language introduced during the website refresh. With a renewed focus on user experience and engagement, the mobile platform now features streamlined interfaces and updated information. "In today's fast-paced healthcare environment, it is essential that our digital platforms are not only reliable but also easy to navigate and visually appealing," said Bill Bentley, National Sales Manager. "Created with our youngest patients in mind, the redesign was thoughtfully developed to be more engaging, age-appropriate, and easy to navigate—helping children and their families feel more supported and empowered throughout their healthcare journey." Key Features and Benefits Unified Design Aesthetic: The mobile app adopts the clean, modern design previously launched on the website, providing a consistent look and feel across all digital touchpoints. Richer Content Experience: The app now features an expanded content database, providing a broader range of resources and information to support users with timely, relevant, and easy-to-access content. Improved Performance: The redesigned app features enhanced performance, with a new backend architecture that allows for faster content updates, easier maintenance, and more frequent improvements to keep the experience fresh and relevant. AMT partnered with Cleveland-Ohio based software company, Stream 9, on the redesign. Their strong track record in software design and development brought deep technical expertise and a strategic approach. "We're fortunate in our business to develop custom software projects for businesses of all kinds; but it's especially rewarding to work on a project that will deliver such a direct benefit to patients and their caregivers. AMT brought a clear vision to the table, and we worked closely together to translate that into a modern, scalable, and user-friendly digital experience," shared Kirk Miesle, Founder of Stream 9. The AMT ONE Source® app is available now on the App Store and Google Play. About AMT: Applied Medical Technology, Inc. (AMT) is a global leader in enteral and surgical devices committed to improving lives through innovation. For 40 years, AMT has bridged the gap between medical technology and patient needs, collaborating with healthcare professionals and users to develop high-quality, life-enhancing solutions. Our holistic approach prioritizes the well-being of the whole person, not just the device they use. View original content to download multimedia: SOURCE Applied Medical Technology, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
